Division of Nephrology, Ente Ospedaliero Cantonale.
Faculity of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
Curr Opin Nephrol Hypertens. 2023 Jul 1;32(4):352-358. doi: 10.1097/MNH.0000000000000893. Epub 2023 Apr 19.
Acute kidney injury (AKI) occurs in approximately 10-15% of patients admitted to hospital and is associated with adverse clinical outcomes. Despite recent advances, management of patients with AKI is still mainly supportive, including the avoidance of nephrotoxins, volume and haemodynamic management and renal replacement therapy. A better understanding of the renal response to injury is the prerequisite to overcome current limitations in AKI diagnostics and therapy.
Single-cell technologies provided new opportunities to study the complexity of the kidney and have been instrumental for rapid advancements in the understanding of the cellular and molecular mechanisms of AKI.
We provide an update on single-cell technologies and we summarize the recent discoveries on the cellular response to injury in proximal tubule cells from the early response in AKI, to the mechanisms of tubule repair and the relevance of maladaptive tubule repair in the transition to chronic kidney disease.
急性肾损伤(AKI)发生于约 10-15%的住院患者,与不良临床结局相关。尽管最近取得了进展,但 AKI 患者的治疗仍主要为支持性治疗,包括避免肾毒性药物、容量和血流动力学管理以及肾脏替代治疗。更好地理解肾脏对损伤的反应是克服当前 AKI 诊断和治疗局限性的前提。
单细胞技术为研究肾脏的复杂性提供了新的机会,并对理解 AKI 的细胞和分子机制的快速进展起到了关键作用。
我们提供了单细胞技术的最新进展,并总结了最近关于近端肾小管细胞损伤反应的发现,从 AKI 的早期反应到小管修复机制,以及小管修复的不适应在向慢性肾脏病转变中的相关性。